TDMS Study 05031-01 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
MERCURIC CHLORIDE
NTP Experiment-Test: 05031-01 Report: PEIRPT05
Study Type: CHRONIC Date: 09/04/94
Route: GAVAGE Time: 16:24:48
Facility: International Research and Development Corp.
Chemical CAS #: 7487-94-7
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5MG/KG 10MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 4 11 8
Dead 5 4 10
Gavage Death 1
Survivors
Terminal Sacrifice 41 35 31
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (50)
Gallbladder (38) (41) (35)
Intestine Large, Cecum (45) (49) (42)
Intestine Large, Colon (49) (50) (48)
Intestine Large, Rectum (44) (46) (49)
Intestine Small, Duodenum (45) (47) (43)
Intestine Small, Jejunum (48) (48) (41)
Liver (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Hepatocellular Carcinoma 2 (4%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 1 (2%) 2 (4%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Mesentery (6) (1) (3)
Pancreas (50) (50) (47)
Salivary Glands (49) (48) (50)
Stomach, Forestomach (48) (50) (48)
Squamous Cell Carcinoma 1 (2%) 1 (2%)
Squamous Cell Papilloma 2 (4%)
Stomach, Glandular (48) (50) (46)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (6) (8) (17)
Heart (50) (50) (50)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5MG/KG 10MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (49) (49) (50)
Adenoma 1 (2%)
Adrenal Gland, Medulla (49) (48) (49)
Pheochromocytoma Benign 1 (2%) 1 (2%) 1 (2%)
Islets, Pancreatic (49) (50) (46)
Adenoma 1 (2%)
Pituitary Gland (49) (47) (45)
Adenoma 2 (4%) 4 (9%) 2 (4%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (49) (49)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (3) (3)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (33%) 1 (33%)
Mediastinum, Hemangiosarcoma 1 (33%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (49) (50)
Adenoma 4 (8%) 1 (2%) 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Teratoma 1 (2%)
Oviduct (1)
Uterus (50) (50) (49)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Leiomyosarcoma 1 (2%)
Cervix, Granular Cell Tumor Benign 1 (2%)
Cervix, Endometrium, Polyp Stromal 1 (2%)
Endometrium, Polyp Stromal 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50)
Lymph Node (44) (44) (48)
Mesenteric, Squamous Cell Carcinoma,
Metastatic, Stomach 1 (2%)
Spleen (49) (50) (48)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 2 (4%) 1 (2%)
Page 3
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5MG/KG 10MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Thymus (41) (39) (43)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (47) (46) (46)
Adenocarcinoma 1 (2%)
Skin (50) (50) (50)
Fibrosarcoma 4 (8%)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50)
Skeletal Muscle (3) (1)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Adenocarcinoma, Metastatic, Harderian Gland 1 (2%)
Alveolar/Bronchiolar Adenoma 2 (4%) 5 (10%) 2 (4%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 2 (4%) 2 (4%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Nose (50) (50) (50)
Trachea (50) (49) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5MG/KG 10MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (1)
Adenocarcinoma 1 (100%)
Adenoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (50)
Urinary Bladder (48) (48) (47)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Lymphoma Malignant Histiocytic 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%)
Lymphoma Malignant Mixed 9 (18%) 8 (16%) 4 (8%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5MG/KG 10MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 23 32 19
Total Primary Neoplasms 29 39 28
Total Animals with Benign Neoplasms 13 14 12
Total Benign Neoplasms 14 15 16
Total Animals with Malignant Neoplasms 14 21 12
Total Malignant Neoplasms 15 24 12
Total Animals with Metastatic Neoplasms 2 4
Total Metastatic Neoplasm 4 8
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5MG/KG 10MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Dead 8 10 8
Moribund 6 4 11
Survivors
Terminal Sacrifice 35 36 31
Dead 1
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (49) (48) (49)
Intestine Large, Rectum (47) (47) (49)
Adenocarcinoma 1 (2%)
Intestine Small, Duodenum (46) (43) (45)
Polyp Adenomatous 1 (2%)
Intestine Small, Ileum (44) (43) (45)
Intestine Small, Jejunum (48) (43) (45)
Liver (50) (50) (50)
Hemangioma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 2 (4%) 2 (4%) 6 (12%)
Hepatocellular Carcinoma, Multiple 3 (6%) 1 (2%)
Hepatocellular Adenoma 1 (2%) 1 (2%)
Hepatocellular Adenoma, Multiple 1 (2%) 1 (2%)
Mesentery (3) (2)
Pancreas (50) (46) (49)
Hemangioma 1 (2%)
Salivary Glands (50) (48) (49)
Stomach, Forestomach (50) (48) (50)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (49) (47) (49)
Tooth (3) (2) (3)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (10) (14) (18)
Vena Cava, Fibrosarcoma, Metastatic, Skin 1 (6%)
Heart (50) (50) (50)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5MG/KG 10MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (50) (49)
Adenoma 1 (2%)
Subcapsular, Adenoma 1 (2%) 1 (2%)
Adrenal Gland, Medulla (45) (50) (49)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Pituitary Gland (48) (47) (47)
Adenoma 1 (2%)
Pars Intermedia, Adenoma 2 (4%) 1 (2%)
Thyroid Gland (49) (47) (49)
Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1)
Mediastinum, Fibrosarcoma, Metastatic, Skin 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Penis (4) (2) (6)
Prostate (46) (49) (46)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50)
Lymph Node (44) (48) (43)
Spleen (50) (49) (49)
Thymus (26) (34) (27)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50)
Fibroma 1 (2%)
Fibrosarcoma 2 (4%) 3 (6%)
Fibrosarcoma, Metastatic 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5MG/KG 10MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2) (2)
Fibrosarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Alveolar/Bronchiolar Adenoma 6 (12%) 5 (10%) 3 (6%)
Alveolar/Bronchiolar Adenoma, Multiple 3 (6%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 4 (8%) 2 (4%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 1 (2%) 1 (2%)
Nose (50) (50) (50)
Trachea (50) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (3) (1)
Adenoma 3 (100%) 1 (100%)
Adenoma, Multiple 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49)
Renal Tubule, Adenocarcinoma 1 (2%)
Renal Tubule, Adenoma 2 (4%)
Urinary Bladder (45) (48) (46)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Lymphoma Malignant Histiocytic 1 (2%)
Lymphoma Malignant Mixed 7 (14%) 2 (4%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 9
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:48
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5MG/KG 10MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 28 20 17
Total Primary Neoplasms 37 27 24
Total Animals with Benign Neoplasms 13 15 10
Total Benign Neoplasms 17 16 12
Total Animals with Malignant Neoplasms 20 10 11
Total Malignant Neoplasms 20 11 12
Total Animals with Metastatic Neoplasms 2 2 2
Total Metastatic Neoplasm 2 2 5
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 10
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------